Nebivolol vs Carvedilol

calendar
2 Nov, 11

Nebivolol is as Effective as Carvedilol in Treatment of Hypertensive CHF Patients

Aim

To compare the effects of long-term treatment of nebivolol with carvedilol on left ventricular ejection fraction (LVEF), exercise capacity and clinical outcomes in hypertensive CHF patients.

Study Patients

Hypertensive CHF patients, with LVEF < 40% and in New York Heart Association (NYHA) functional class I, II or III (N = 160)

Study Groups

  • Nebivolol (n = 80)
  • Carvedilol (n = 80)

Nebivolol was initiated at 1.25 mg/day. If tolerated, dose was sequentially up-titrated every week. Target dose of 10 mg/day was reached by week 4.

Carvedilol was initiated at 3.125 mg twice daily. If tolerated, dose was sequentially up-titrated every week. Target dose of 50 mg/day was reached by week 6.

Target dose of Nebivolol and Carvedilol was reached in 60 and 57 patients, respectively.

Assessments

  • Clinical evaluation
  • Left ventricular ejection fraction (LVEF)
  • 6-minute walking test (6MWT)

Study Duration

24 months

Results

Nebivolol and Carvedilol significantly improved LVEF by a similar extent

Nebivolol and Carvedilol significantly improved exercise capacity by a similar extent

Nebivolol and Carvedilol significantly improved NYHA class by a similar extent

Nebivolol and Carvedilol caused significant and similar decreases in HR and SBP

Rate of clinical events was similar in Nebivolol and Carvedilol groups

Conlusion

Nebivolol and Carvedilol appear to be similarly effective in the long-term treatment of hypertensive CHF patients.

J Cardiac Fail 2011.(Epub ahead of print)